eCARIBOU: A Remote Electronically Delivered Integrated Care Pathway: A Feasibility Study

Sponsor
Centre for Addiction and Mental Health (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05086120
Collaborator
York University (Other)
12
1
17.8

Study Details

Study Description

Brief Summary

This is a one-armed observational study and feasibility trial of a remote electronically-delivered integrated care pathway for the treatment of adolescents. Eligible participants are between the ages of 13 and 18, inclusive, who have a primary diagnosis of major depressive disorder. Outcomes of interest are recruitment rates and participation in pathway components, including: appointments, measure-completion and use of electronically-delivered cognitive behavioural therapy.

Condition or Disease Intervention/Treatment Phase
  • Other: eCARIBOU
N/A

Detailed Description

Introduction: Depression is common and debilitating in the adolescent age range. Geography or other logistical barriers may prevent youth from accessing care. Progress in the treatment of youth that uses their tendencies to engage in electronically mediated contacts (e.g., text, online videos, and livestream video chat) can strategically address depressive disorders to overcome these barriers.

Methods: The Principal Investigator will conduct a pilot single-arm trial to assess the feasibility of a 16-week remote electronically delivered integrated care pathway (ICP) for the treatment of adolescents (age 13-18) with major depressive disorder. CBT components being delivered has been tested in the age 18-30 with depression. The ICP includes: tele-psychiatry appointments, online measurement-based care, internet-based cognitive behavioural therapy combined with mindfulness training, and text-based health coaching. Eligible subjects will be recruited from Child, Youth and Family services at the Centre for Addiction and Mental Health. The Principal Investigator aims to recruit 12 participants.

Outcomes: Feasibility outcomes are of the primary interest; namely, recruitment rates, proportion of psychiatry appointments attended, proportion of self-report measures completed, proportion of online CBT videos viewed, number of text-exchanges between youth and health coaches, physical activity levels and qualitative feedback from youth about their experiences. Primary clinical outcomes will be described via self-reported depressive symptoms using the Mood and Feelings Questionnaire. Secondary outcomes include self-reported anxiety (anxiety-related subscales of the Revised Children's Anxiety and Depression Scale) and function (Youth Columbia Impairment Scale). The Principal Investigator will also measure self-injurious thoughts and behaviours using the Columbia Suicide Severity Rating Scale.

Discussion: If results confirm hypotheses that youth can be feasibly treated with a remote electronically delivered ICP, further efficacy testing may be performed to assess this as a viable option for service delivery that reduces barriers to care.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
12 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
Adolescents (age 13-18) with major depressive disorder.Adolescents (age 13-18) with major depressive disorder.
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Remote Electronically Delivered Integrated Care Pathway for Adolescents With Major Depressive Disorder: A Feasibility Study
Anticipated Study Start Date :
Jan 4, 2022
Anticipated Primary Completion Date :
Jul 1, 2023
Anticipated Study Completion Date :
Jul 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Remote Electronically Delivered Integrated Care Pathway (ICP)

The remote electronically-delivered ICP (also known as eCARIBOU) will consist of psychiatry appointments through telemedicine every 4 weeks over 16 weeks, where the youth is at home. Prior to these appointments, measures (i.e., Mood and Feelings Questionnaire - MFQ) will be sent to the youth to be completed. Change in measure scores will be reviewed collaboratively between the psychiatrist and the youth to assist in making treatment decisions. The medication algorithm in the in-person ICP will be used to guide these decisions. The psychiatrist will also administer the Columbia Suicide Severity Rating Scale (C-SSRS) at each telepsychiatry appointment to monitor risk. Concurrently, youth will be offered internet-based Cognitive Behavioural Therapy (iCBT) and health-coaching via text.

Other: eCARIBOU
A 16 week remote electronically deliver Integrated Care Pathway (ICP) for adolescents (13-18 years old) with Major Depressive Disorder (MDD).

Outcome Measures

Primary Outcome Measures

  1. Recruitment [6 months]

    Time it takes to recruit 12 participants to the study

  2. Number of Psychiatry Appointments [16 weeks]

    Proportion of scheduled psychiatry appointments attended (number attended divided by 4 for each participant)

  3. Number of iCBT Content Viewed [16 weeks]

    Proportion of online CBT videos viewed per participant (number viewed divided by 54)

  4. Number of Health Coach Text Messages [16 weeks]

    Number of text messages the participant sent to the health coach (count data)

  5. Fitbit Usage [16 weeks]

    Number of days the fitbit is worn and the percentage of data collected

  6. Psychiatric Management [16 weeks]

    Number of events involving of self-harm behaviour/suicidal ideation that required acute psychiatric management (where the study psychiatrist needs to communicate with the youth and/or family members outside of regular appointments every 4 weeks).

  7. Youth's Experience with eCARIBOU [16 weeks]

    Qualitative Interview feedback from youth pertaining to the intervention - including ease of use, content relevance, level of engagement with the intervention

  8. ICP Deviations [16 weeks]

    Frequency of deviations from the pathway and any documented reasons for deviations

Eligibility Criteria

Criteria

Ages Eligible for Study:
13 Years to 18 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • 13-18 years old at baseline

  • Mood and Feelings Questionnaire - Childhood, long version (MFQ) score of ≥22

  • Diagnosis of Major Depressive Disorder by impression from the referring psychiatrist and confirmed using the KSADS

  • Internet access at home

  • Access to a smartphone for personal and private use, with an associated standard data plan (ie. greater than or equal to 500 MB/month)

  • Able to speak and read English fluently

Exclusion Criteria:
  • Individuals that arecurrently receiving structured psychotherapy

  • Clinically significant suicidal ideation that is defined as 'imminent intent' or attempted suicide in the past 6 months

  • Co-morbid diagnosis of borderline personality disorder (as assessed by the Childhood Interview for Borderline Personality Disorder) (Zanarini, 2003), schizophrenia, bipolar disorder, moderate-to-severe eating disorder, obsessive compulsive disorder and/or severe alcohol/substance use disorder in the past 3 months

  • Youth with known or clinically suspected intellectual disability or autism spectrum disorder

  • Youth who are not able to provide informed consent for any other reason

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Centre for Addiction and Mental Health
  • York University

Investigators

  • Principal Investigator: Darren Courtney, MD, Centre for Addiction and Mental Health

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Darren Courtney, Clinician Scientist with the Cundill Centre for Child and Youth Depression and a Staff Psychiatrist in the Youth Addictions and Concurrent Disorders Service, Centre for Addiction and Mental Health
ClinicalTrials.gov Identifier:
NCT05086120
Other Study ID Numbers:
  • 121/2019-01
First Posted:
Oct 20, 2021
Last Update Posted:
Dec 8, 2021
Last Verified:
Dec 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Darren Courtney, Clinician Scientist with the Cundill Centre for Child and Youth Depression and a Staff Psychiatrist in the Youth Addictions and Concurrent Disorders Service, Centre for Addiction and Mental Health
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 8, 2021